Effects of D-myo-Inositol-1,2,6-triphosphate on eicosanoid formation in burned skin.
D-myo-Inositol-1,2,6-triphosphate (IP3) has been shown to reduce edema and progressive ischemia following experimental skin burns. The mechanism(s) are not identified but could be related to antiinflammatory effects of the agent. In the present ex vivo study we compared the effects of IP3 with those of saline and indomethacin on eicosanoid formation by normal and burned rat skin. In burned skin IP 3 treatment reduced the release of thromboxane B2 (TXB2) (P < 0.01) and leukotriene B4 (LTB 4) (P < 0.05) but there was only a weak trend for less prostaglandin E (PGE) compared to burned control animals receiving saline. Indomethacin reduced the release of TXB2 (P < 0.01), and PGE (P < 0.001), but not LTB 4 from burned skin compared to skin from saline-treated burned animals. In non-burned skin IP 3 increased the release of PGE (P < 0.01) and LTB 4 (P < 0.01), but did not significantly influence TXB2 accumulation in the incubation fluid compared to the saline-treated group. Indomethacin reduced the release of TXB2 (P < 0.001) and PGE (P < 0.001), but increased LTB 4 (P < 0.001) in normal skin compared to the saline-treated group. In conclusion, IP 3 inhibited the release of TXB2 and LTB 4 from burned skin ex vivo, but increased PGE and LTB 4 release from normal skin. These results suggest that the mode of action of IP 3 differs from that of nonsteroidal antiinflammatory drugs. The effects of IP 3 on the arachidonic acid cascade also seem to differ in burned versus normal skin.
Tarnow
P
P
Department of Physiology, Göteborg University, Sweden.
Cassuto
J
J
Jönsson
A
A
Nellgård
P
P
Bennett
A
A
Tavares
I A
IA
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002056:Burns / Q000378:metabolism*; D015777:Eicosanoids / Q000378:metabolism*; D007213:Indomethacin / Q000494:pharmacology; D007295:Inositol Phosphates / Q000494:pharmacology*; D007975:Leukotriene B4 / Q000378:metabolism; D008297:Male; D011458:Prostaglandins E / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000187:drug effects / Q000378:metabolism*; D013929:Thromboxane B2 / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015777:Eicosanoids; D007295:Inositol Phosphates; D011458:Prostaglandins E; D007975:Leukotriene B4; D013929:Thromboxane B2; C059368:atrinositol; D007213:Indomethacin